Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intracapsular RAK Cells for Glioma and Brain Metastases
NCT05459441Phase 1Unknown
- Sponsor
- Shanghai Pudong Hospital
- Start
- Jan 2022
- Primary completion
- Jun 2023
- Modality
- Prophylactic Vaccines, Cell Therapies, Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of RAK cells in glioma and brain metastases (2 arms), sponsored by Shanghai Pudong Hospital. Primary endpoint: Clinical response rate at 24 months. Status: unknown.
02
Drugs
RAK cells
03
Conditions
gliomabrain metastases
Beyond the preview
Go deeper on NCT05459441.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05459441.